VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Privilege of attending the ESC Congress in London.Hugh 🌟

<< Previous

Bullboard Posts

Next >>

Comment by jopatcloon Sep 03, 2024 6:59am

52 Views

Post# 36205692

RE:Privilege of attending the ESC Congress in London.Hugh 🌟

Dario Freitas and Richard Simpson like this

Over the long weekend, several of us had the privilege of attending the ESC Congress in London. This event was a fantastic platform for connecting with leading experts, potential partners, and key players in the finance community. Our time there was not only inspiring but also reinforced our confidence in the exciting path ahead for Ventripoint.

Our unique capability of delivering cMRI-level accuracy for right ventricle volumes and ejection fractions using echocardiography has clearly set us apart. The demand for similar accuracy across other heart chambers is evident, and our progress in enhancing VMS+ brings us closer to transitioning from clinical research to mainstream clinical practice. We're moving from general promotion to a more targeted approach, focusing on specific use cases and indications that will drive real impact.

Since Ventripoint's inception, our technology has been featured in approximately 60 publications, covering congenital heart defects, chemotherapy-induced cardiotoxicity, and pulmonary hypertension. The congress further solidified our belief that there are numerous additional opportunities to develop new propositions addressing critical clinical needs. These prospects offer considerable value and present multi-faceted market opportunities for our industry.

Our commercial team is actively exploring these opportunities to refine our revenue and business models, positioning us for a successful growth phase. Additionally, we've begun exploring ways to expand our sales team to strengthen our market presence as we approach the autumn and year-end.

In summary, the weekend was a highly productive and promising step forward. Stay tuned for more updates as we continue to build on this momentum.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project